S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial - Concepedia

Concepedia

Publication | Open Access

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial

DOI Full Paper Access

86

Citations

13

References

2017

Year

Yasuhide Yamada, Tadamichi Denda, Makio Gamoh, Ichiro Iwanaga, Satoshi Yuki, Hideki Shimodaira, Masato Nakamura, Tatsuro Yamaguchi, Hisatsugu Ohori, Kôji Kobayashi,

Annals of Oncology

References

	Year	Citations

Page 1